Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06513208Phase 4Recruiting

Ketorolac Effects on Post-operative Pain and Lumbar Fusion

Role: lead

NCT06487585Phase 4Recruiting

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

Role: lead

NCT06596200Phase 4Not Yet Recruiting

Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy

Role: lead

All 3 trials loaded